Cigna Group (CI)
Fair ValueFondamentale
78
Prezzo
$271.83
Capitalizzazione
$71.83B
Parte 1 · Quanto vale l'azienda
Panoramica
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Generato il 18 settembre 2026 con claude-haiku-4-5 — condiviso con tutti gli utenti
È l'azienda che più assomiglia a Cigna: vende piani sanitari alle stesse grandi aziende americane e, con Optum Rx, si contende con Express Scripts di Evernorth gli stessi contratti di gestione dei farmaci.
Con Aetna si contende gli stessi iscritti dei piani aziendali e commerciali, e con CVS Caremark è uno dei tre gestori di benefit farmaceutici che si dividono il mercato americano insieme a Express Scripts.
Primo operatore del circuito Blue Cross Blue Shield, si contende gli stessi piani aziendali e individuali negli stessi stati americani, e con CarelonRx sfida Evernorth sulla gestione dei farmaci.
È il maggiore assicuratore sui mercati individuali americani, dove si contende con Cigna Healthcare gli stessi clienti privati agevolati, stato per stato.
Assicuratore mutualistico del circuito Blue Cross presente in Illinois, Texas e altri tre stati, è il quinto operatore commerciale americano e dal marzo 2025 possiede anche il ramo Medicare comprato proprio da Cigna: i due si affrontano sui grandi contratti aziendali nazionali.
Stato Patrimoniale e Liquidità
Ricavi
$282.38B
Ultimi 12 mesi (al 30/06/2026)
Utile Netto
$6.42B
Ultimi 12 mesi (al 30/06/2026)
Free Cash Flow
-
Patrimonio Netto Totale
$41.71B
Passività Totali
$116.05B
Rapporto di Liquidità
0.85
Copertura Interessi
7.03
Debito/EBITDA
2.75
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$324.54
Prezzo Attuale
$271.83
Margine di Sicurezza
+16.2%
Range Fair Value
$210.95 - $438.13
Intervallo di dispersione tra i metodi di valutazione usati, non una stima statisticamente calibrata.
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
11.25
ROE
14.3%
Rapporto P/B
1.69
P/FCF
-
Margine Lordo
20.6%
ROIC
7.8%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
7.8%
WACC
6.5%
ROIC − WACC
+1.2 pp
Il ROIC supera il costo del capitale: l'azienda sta creando valore per gli azionisti.
Criteri di Analisi Fondamentale
Superati (18)
- EPS shows upward trend
- EPS CAGR 13.33%
- Price CAGR 7.73%
- ROIC 7.7%
- P/B Ratio 1.69
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Price below Graham Number
- ROE 15.2%
- Revenue Growth 5Y 11.4%
- Analyst Consensus 76% Buy
- Earnings Quality (OCF/NI) 1.60
- Share Dilution -5.2%
- Net Margin Trend 2.3% vs 1.9%
- Piotroski F-Score 8/9
Non superati (5)
- Gross Margin 20.6%
- Operating Margin 3.5%
- Low reliance on intangibles
- DCF valuation (Fairly valued)
- Earnings Surprise avg -0.6%
Non disponibili (5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Salute finanziaria forte
Qualità degli Utili
Alta qualità: utili supportati da cash
Diluizione Azionaria
Riacquisto azioni. Favorevole agli azionisti
Partecipazioni istituzionali
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. David Michael Cordani | Executive Chairman of the Board | 60 |
| Mr. Brian Case Evanko C.F.A. | President, CEO & Director | 48 |
| Ms. Ann M. Dennison | Executive VP & CFO | 54 |
| Ms. Nicole Susan Jones J.D. | Executive Vice President, Chief Administrative Officer & Chief Human Resources Officer | 54 |
| Mr. F. Everett Neville | Executive VP & Special Advisor to the CEO | 60 |
| Ms. Jamie Kates | Senior VP & Tax and Global Chief Accounting Officer | 44 |
| Mr. Durga Prasad Koka | Executive Vice President & Global Chief Information Officer | - |
| Mr. Ralph Giacobbe | Senior Vice President of Investor Relations | - |
| Ms. Andrea Nelson | EVP, General Counsel & Corporate Secretary | - |
| Ms. Melissa Skottegaard | Executive Vice President, Chief Marketing & Communications Officer | - |
Rischio Audit
1
Rischio CdA
4
Rischio Compensi
7
Rischio Diritti Azionisti
7
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Documenti
- Vedi documento
Relazione annuale (10-K)
Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.
Depositato il 2026-02-26
- Vedi documento
Relazione trimestrale (10-Q)
Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.
Depositato il 2026-07-30
- Vedi documento
Comunicazione price-sensitive (8-K)
Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.
Depositato il 2026-09-30
via SEC EDGAR
Storico Ricavi
via SEC EDGAR
Ultime Notizie
Ultime notizie per CI, da Markets Gazette.
- 23d agoNEUTRALCigna Healthcare on Business Strategy
Jason Sadler, International Health Global President at Cigna Healthcare, provided insights into the company's business strategy, addressing the dual forces of increasing AI adoption and escalating healthcare expenditures. While the discussion highlights Cigna's navigation of these significant industry trends, it does not present specific financial figures or forward-looking guidance that would indicate a definitive positive or negative impact on the company's immediate stock performance. Investors will monitor Cigna's strategic execution in response to these evolving market dynamics.
- 5/22/2026NEUTRALHere's How Much You Would Have Made Owning Cigna Group Stock In The Last 20 Years
An analysis of The Cigna Group's stock performance over the past two decades reveals a significant historical return for investors. While specific figures are not detailed in this summary, the article implies substantial long-term gains. This historical perspective is crucial for investors evaluating Cigna's potential for future growth and stability, offering insights into its resilience and market position through various economic cycles. The focus remains on past performance rather than current catalysts.
- 3/6/2026POSITIVEHere's How Much $1000 Invested In Cigna Group 15 Years Ago Would Be Worth Today
An investment of $1000 in Cigna Group 15 years ago would have grown to approximately $10,500 today, representing a substantial return on investment. This performance highlights the company's long-term growth trajectory and its ability to generate significant shareholder value over an extended period. Investors who held Cigna stock through various market cycles would have benefited from its strategic initiatives and market positioning within the health insurance and services sector. The impressive growth suggests a robust business model and effective management.
- 3/3/2026NEGATIVECigna Stock Falls After CEO Retirement Announcement
Shares of The Cigna Group (NYSE:CI) experienced a significant decline on Tuesday, following the announcement of CEO David Cordani's retirement. The news immediately triggered a negative market reaction, highlighting investor sensitivity to leadership changes in major corporations. Cordani, a key figure for the healthcare giant, leaves a void that generates uncertainty about the company's future strategic and operational direction. Analysts suggest that the leadership transition could lead to a period of volatility for the stock, as the market awaits clarity on subsequent plans and the identity of the successor. For investors, this event underscores the importance of managerial stability in complex sectors like healthcare.
- 3/3/2026NEUTRALCigna’s longtime CEO to step down as health insurers face growing scrutiny
Cigna Group, a major player in the health insurance sector, has announced a significant leadership transition. David Cordani, who has served as CEO for an impressive 27 years, will step down. He will be succeeded by Brian Evanko, a seasoned company veteran, ensuring a degree of continuity in leadership. This change comes at a time when health insurers are facing increased scrutiny, adding complexity to the new CEO's mandate. For investors, the appointment of an internal successor like Evanko suggests a focus on stability and a continuation of existing strategies, potentially mitigating immediate market volatility. However, the broader industry challenges mean Evanko will need to navigate a demanding regulatory and competitive landscape, making his strategic direction crucial for Cigna's future performance.
via Markets Gazette